| Literature DB >> 32722034 |
Soad Taha1, Ibrahim El-Sherbiny2, Toshiki Enomoto3, Aida Salem4, Emiko Nagai3, Ahmed Askar5, Ghada Abady4, Mahmoud Abdel-Hamid1.
Abstract
Curcumin is one of the most common spices worldwide. It has potential benefits, but its poor solubility and bioavailability have restricted its application. To overcome these problems, this study aimed to assess the efficacy of sodium caseinate (SC), α-lactalbumin (α-La), β-lactoglobulin (β-lg), whey protein concentrate (WPC) and whey protein isolate (WPI) as nanocarriers of curcumin. Furthermore, the antioxidant, anticancer and antimicrobial activities of the formed nanoparticles were examined. The physicochemical characteristics of the formed nanoparticles as well as the entrapment efficiency (%) and the in vitro behavior regarding the release of curcumin (%) were examined. The results showed that the formation of curcumin-milk protein nanoparticles enhanced both the entrapment efficiency and the in vitro behavior release of curcumin (%). Cur/β-lg nanoparticles had the highest antioxidant activity, while SC and WPC nanoparticles had the highest anticancer effect. The antimicrobial activity of the formed nanoparticles was much higher compared to curcumin and the native milk proteins.Entities:
Keywords: anticancer; antimicrobial activities; antioxidant; curcumin; milk proteins; nanoparticles
Year: 2020 PMID: 32722034 PMCID: PMC7466329 DOI: 10.3390/foods9080986
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Particle size, zeta potential and entrapment efficiency (EE %) of curcumin-loaded milk protein nanoparticles.
| Treatments | Particle Size (nm) | Zeta Potential | EE% | pH |
|---|---|---|---|---|
| Cs/SCNPs | 328.67 b ± 47.55 | −12.73 cd ± 0.87 | - | 5.00 |
| Cs/α-LaNPs | 334.90 b ± 5.84 | −12.70 cd ± 0.44 | - | 5.21 |
| Cs/β-lgNPs | 310.53 bc ±13.17 | −11.13 c ± 0.64 | - | 5.00 |
| Cs/WPI NPs | 275.33 c ± 30.89 | 17.30 b ± 1.90 | - | 4.30 |
| Cs/WPC NPs | 318.17 bc ± 33.98 | −14.03 d ± 1.21 | - | 5.30 |
| Cur-Cs/SCNPs | 278.10 c ± 16.89 | −12.63 cd ± 2.11 | 72.27 e ± 0.13 | 5.20 |
| Cur-Cs/α-La NPs | 290.83 bc ± 47.17 | −19.50 e ± 0.17 | 74.67 c ± 0.06 | 5.31 |
| Cur-Cs/β-lg NPs | 274.80 c ± 8.84 | −14.83 d ± 2.58 | 73.97 d ± 0.12 | 5.30 |
| Cur-Cs/WPI NPs | 462.80 a ± 6.15 | −13.57 d ± 3.23 | 76.30 b ± 0.10 | 5.42 |
| Cur-Cs/WPC NPs | 439.90 a ± 2.95 | 27.73 a ± 0.81 | 77.27 a ± 0.06 | 4.20 |
Different superscripts (a–e) in the same column are significantly different (p ˂ 0.05). SCNPs: sodium caseinate nanoparticles; WPI: whey protein isolate; WPC: whey protein concentrate; NPs: nanoparticles.
Figure 1Fourier-transform infrared (FTIR) spectra of chitosan (Cs), curcumin (Cur), Sod. caseinate (SC), α-lactalbumin (α-La), β-lactoglobulin (β-lg), whey protein isolate (WPI), whey protein concentrate (WPC) and curcumin loaded nanoparticles (Cur NPs).
Figure 2Transmission electron microscope (TEM) images of curcumin-loaded milk protein nanoparticles. (A) Cur-SC NPs, (B) Cur-α-La NPs, (C) Cur-β-lg NPs, (D) Cur-WPI NPs, (E) Cur-WPC NPs.
Figure 3In vitro release profiles of curcumin from curcumin–milk protein nanoparticles.
Antioxidant activity (radical scavenging activity %) of different concentrations of native milk proteins, chitosan–milk protein nanocomposite and curcumin-loaded milk protein nanoparticles.
| Treatments | Concentration (mg/mL) | Mean | ||
|---|---|---|---|---|
| 2.5 | 5 | 10 | ||
| Chitosan | 46.12 ± 2.9 | 54.08 ± 3.9 | 60.32 ± 6.7 | 53.51 ± 4.5 |
| Curcumin | 41.60 ± 3.5 | 54.02 ± 4.0 | 62.13 ± 2.9 | 52.58 ± 3.5 |
| SC | 39.18 ± 3.0 | 42.75 ± 3.3 | 52.28 ± 3.7 | 44.74 ± 3.3 |
| CS/SCNPs | 39.97 ± 2.7 | 50.48 ± 2.7 | 66.90 ± 3.5 | 52.45 ± 3.0 |
| Cur-Cs/SCNPs | 49.17 ± 4.4 | 60.61 ± 4.4 | 67.54 ± 3.5 | 59.11 ± 4.1 |
| α-La | 36.15 ± 1.7 | 48.38 ± 3.6 | 56.55 ± 2.1 | 47.03 ± 2.5 |
| CS/α-LaNPs | 47.06 ± 2.8 | 56.90 ± 2.5 | 62.51 ± 3.0 | 55.49 ± 2.7 |
| Cur-CS/α-La NPs | 53.82 ± 2.0 | 59.35 ± 2.9 | 66.44 ± 1.9 | 59.87 ± 2.3 |
| β-lg | 43.70 ± 2.9 | 53.51 ± 2.0 | 60.49 ± 2.8 | 52.57 ± 2.6 |
| CS/βlgNPs | 46.86 ± 3.1 | 54.14 ± 3.3 | 65.90 ± 1.2 | 55.63 ± 2.5 |
| Cur-Cs/βlg NPs | 48.08 ± 2.8 | 61.62 ± 2.9 | 69.05 ± 3.5 | 59.58 ± 3.1 |
| WPI | 43.26 ± 3.1 | 50.52 ± 6.8 | 60.92 ± 1.9 | 51.57 ± 3.9 |
| Cs/WPI NPs | 51.10 ± 3.8 | 55.10 ± 2.4 | 66.49 ± 2.5 | 57.56 ± 2.9 |
| Cur-Cs/WPINPs | 50.11 ± 3.3 | 55.08 ± 1.6 | 68.57 ± 2.5 | 57.92 ± 2.5 |
| WPC | 36.30 ± 2.0 | 52.44 ± 2.4 | 61.03 ± 4.8 | 49.92 ± 3.1 |
| Cs/WPC NPs | 47.03 ± 3.9 | 57.26 ± 2.9 | 65.40 ± 2.7 | 56.56 ± 3.2 |
| Cur-Cs/WPCNPs | 49.03 ± 4.2 | 56.20 ± 3.1 | 63.30 ± 2.6 | 56.18 ± 3.3 |
| Mean | 45.21 ± 3.1 | 54.26 ± 3.2 | 63.28 ± 3.0 | |
Least significant difference (L.S.D.) value at 0.05: concentrations: 0.72, treatments: 1.72, interaction: 2.98.
Anticancer activity of different concentrations of native proteins, chitosan–milk protein nanocomposite and curcumin-loaded milk protein nanoparticles against HepG2 cell lines.
| Treatments | Anticancer Activity %/Concentrations (mg/mL) | Mean | ||
|---|---|---|---|---|
| 2.5 | 5 | 10 | ||
| Chitosan | 34.97 ± 1.03 | 73.35 ± 2.25 | 91.79 ± 1.96 | 66.70 ± 1.75 |
| Curcumin | 54.06 ± 1.94 | 81.08 ± 2.32 | 95.07 ± 2.93 | 76.74 ± 2.40 |
| SC | 33.71 ± 1.29 | 71.33 ± 2.12 | 93.05 ± 2.95 | 66.03 ± 2.12 |
| CS/SCNPs | 40.4±3.35 | 82.95±3.35 | 95.29±1.71 | 72.88±2.80 |
| Cur-Cs/SCNPs | 46.49±2.64 | 86.36±2.64 | 97.31±2.04 | 76.72±2.44 |
| α-La | 36.75±1.75 | 70.70±2.40 | 92.04±1.36 | 66.50±1.84 |
| CS/α-LaNPs | 38.23±1.77 | 76.67 ± 1.43 | 94.11 ± 1.89 | 69.67 ± 1.70 |
| Cur-Cs/α-La NPs | 45.9 ± 1.40 | 81.79 ± 1.19 | 96.80 ± 3.30 | 74.83 ± 1.96 |
| βlg | 17.55 ± 2.55 | 48.36 ± 4.64 | 83.58 ± 2.42 | 49.83 ± 3.20 |
| CS/βlgNPs | 40.88 ± 2.12 | 70.84 ± 2.56 | 92.55 ± 2.45 | 68.09 ± 2.38 |
| Cur-Cs/βlg NPs | 43.27 ± 1.73 | 85.54 ± 1.37 | 95.80 ± 2.20 | 74.87 ± 1.77 |
| WPI | 18.59 ± 1.41 | 53.91 ± 1.19 | 76.64 ± 1.66 | 49.71 ± 1.42 |
| CS/WPINPs | 43.03 ± 1.53 | 81.69 ± 1.91 | 93.81 ± 1.19 | 72.84 ± 1.54 |
| Cur-Cs/WPINPs | 49.9 ± 1.10 | 82.20 ± 2.79 | 96.31 ± 2.81 | 76.14 ± 2.23 |
| WPC | 30.63 ± 2.37 | 81.29 ± 3.71 | 93.68 ± 2.18 | 68.53 ± 2.75 |
| Cs/WPC NPs | 42.74 ± 2.26 | 82.53 ± 1.07 | 95.27 ± 3.23 | 73.51 ± 2.19 |
| Cur-Cs/WPCNPs | 48.68 ± 4.32 | 80.36 ± 3.06 | 98.07 ± 3.07 | 75.70 ± 3.48 |
| Mean | 39.16 ± 2.03 | 75.94 ± 2.35 | 93.01 ± 2.31 | |
L.S.D. value at 0.05: concentrations: 0.69, treatments: 1.63, interaction: 2.83.
Anticancer activity of different concentrations of native proteins, chitosan–milk protein nanocomposite and curcumin-loaded milk protein nanoparticles against MCF7 cell lines.
| Treatments | Anticancer Activity (%)/Concentrations (mg/mL) | |||
|---|---|---|---|---|
| 2.5 | 5 | 10 | Mean | |
| Chitosan | 33.22 ± 1.7 | 67.21 ± 1.6 | 92.21 ± 2.8 | 64.21 ± 2.0 |
| Curcumin | 33.4 ± 1.7 | 73.27 ± 2.0 | 93.52 ± 2.0 | 66.73 ± 1.9 |
| SC | 25.25 ± 2.1 | 71.27 ± 2.6 | 92.93 ± 2.1 | 63.15 ± 2.3 |
| CS/SCNPs | 35.86 ± 3.9 | 75.91 ± 3.9 | 93.33 ± 1.8 | 68.37 ± 3.7 |
| Cur-Cs/SCNPs | 50.84 ± 2.9 | 78.15 ± 2.9 | 96.88 ± 5.5 | 75.29 ± 3.7 |
| α-La | 30.27 ± 2.8 | 71.27 ± 2.0 | 93.25 ± 1.8 | 64.93 ± 2.2 |
| CS/α-La NPs | 41.61 ± 3.1 | 75.13 ± 4.1 | 94.78 ± 3.7 | 70.51 ± 3.6 |
| Cur-Cs/α-La NPs | 51.26 ± 2.3 | 77.18 ± 2.2 | 98.31 ± 1.8 | 75.58 ± 2.1 |
| βlg | 19.24 ± 1.8 | 50.98 ± 3.1 | 85.37 ± 4.2 | 51.86 ± 3.0 |
| CS/βlgNPs | 44.08 ± 2.9 | 61.58 ± 2.5 | 91.93 ± 2.1 | 65.86 ± 2.5 |
| Cur-Cs/βlg NPs | 53.63 ± 2.6 | 74.61 ± 3.4 | 98.47 ± 3.5 | 75.57 ± 3.5 |
| WPI | 16.63 ± 2.5 | 48.80 ± 4.1 | 83.17 ± 2.8 | 49.53 ± 3.1 |
| CS/WPINPs | 41.65 ± 2.4 | 74.78 ± 3.8 | 94.2 ± 1.3 | 70.21 ± 2.5 |
| Cur-Cs/WPINPs | 52.43 ± 2.8 | 77.87 ± 5.9 | 98.48 ± 5.5 | 76.26 ± 4.7 |
| WPC | 17.87 ± 2.1 | 62.24 ± 2.6 | 76.30 ± 3.0 | 52.14 ± 2.6 |
| Cs/WPC NPs | 33.26 ± 2.2 | 74.79 ± 3.3 | 93.86 ± 2.3 | 67.30 ± 2.6 |
| Cur-Cs/WPCNPs | 50.03 ± 1.5 | 75.96 ± 2.9 | 98.06 ± 2.5 | 74.68 ± 2.3 |
| Mean | 37.09 ± 2.4 | 70.06 ± 3.2 | 89.12 ± 2.9 | |
L.S.D. value at 0.05: concentrations: 1.15, treatments: 2.73, interaction: 4.7.
Antimicrobial activity of native proteins, chitosan–milk protein nanocomposite and curcumin-loaded milk protein nanoparticles.
| Treatments | Inhibition Zone (mm) | ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| Chitosan | 15 g ± 4 | 19 bcd ± 2 | 21 fg ± 3 | 14 f ± 4 | 12 e ± 2 |
| Curcumin | 16 fg ± 3 | 20 bc ± 3 | 23 ef ± 2 | 16 ef ± 3 | 21 bc ± 3 |
| SC | 19 efg ± 2 | 25 a ± 2 | 26 cde ± 4 | 15 f ± 3 | 14 e ± 2 |
| CS/SCNPs | 22 cde ± 3 | 17 cde ± 3 | 28 bcd ± 3 | 20 cde ± 3 | 20 cd ± 4 |
| Cur-Cs/SCNPs | 27 ab ± 3 | 21 b ± 4 | 31 ab ± 4 | 25 ab ± 4 | 28 a ± 3 |
| α-La | 0 h ± 0 | 0 f ± 0 | 0 h ± 0 | 0 g ± 0 | 20 cd ± 3 |
| CS/α-LaNPs | 20 def ± 3 | 15 e ± 4 | 25 def ± 3 | 25 ab ± 2 | 22 bc ± 3 |
| Cur-Cs/α-La NPs | 24 bcd ± 3 | 20 bc ± 3 | 30 abc ± 3 | 28 a ± 3 | 25 ab ± 2 |
| Βlg | 0 h ± 0 | 0 f ± 0 | 0 h ± 0 | 0 g ± 0 | 0 f ± 0 |
| CS/βlgNPs | 25 bc ± 2 | 19 bcd ± 2 | 30 abc ± 3 | 24 abc ± 3 | 16 de ± 3 |
| Cur-CS/βlgNPs | 30 a ± 3 | 22 ab ± 3 | 33 a ± 2 | 26 ab ± 3 | 21 bc ± 3 |
| WPI | 0 h ± 0 | 0 f ± 0 | 0 h ± 0 | 0 g ± 0 | 0 f ± 0 |
| Cs/WPI NPs | 20 def ± 3 | 14 e ± 3 | 28 bcd ± 3 | 15 f ± 2 | 16 de ± 3 |
| Cur-Cs/WPI NPs | 28 ab ± 3 | 20 bc ± 3 | 32 ab ± 3 | 22 bcd ± 3 | 21 bc ± 3 |
| WPC | 0 h ± 0 | 0 f ± 0 | 16 g ± 1 | 0 g ± 0 | 0 f ± 0 |
| Cs/WPC NPs | 24 b-d ± 3 | 16 de ± 3 | 22 ef ± 3 | 18 def ± 3 | 15 e ± 3 |
| Cur-Cs/WPC NPs | 31 a ± 4 | 22 ab ± 3 | 28 bcd ± 3 | ‘20 cde ± 3 | 23 bc ± 2 |
Different superscripts (a–g) in the same column are significantly different (p ˂ 0.05).